Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw 12-13 June 2007.

Slides:



Advertisements
Similar presentations
Preparation, characterization and establishment of a WHO International Biological Reference Preparation Dr Sjoerd Rijpkema Division of Bacteriology NIBSC.
Advertisements

Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Replacement of the 1 st Parvovirus B19 DNA International Standard SoGAT XXI, Brussels, 28th-29th May 2009 Sally Baylis.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
NIBSC Multiplex Proficiency Panel - A multicentre study
Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
Generic Automated Sample Preparation for Commercial NAT Assays
ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)
BioLife Plasma Services Experience with HBV NAT Testing
1 HBV Genotype Panel Michael Chudy Section of Molecular Virolgy Division of Virology SoGAT XXI Meeting Brussels, May 2009.
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
DEVELOPMENT OF THE TOOLS FOR PCR-DETECTION OF HEPATITIS A AND C VIRUSES IN INTRAHOSPITAL VIRAL CONTAMINATION RESEARCH. 1 D. I. Ivanovsky Virology Institute,
Hepatitis E Virus – Progress in Standardization of NAT-Based Assays Blood Products Advisory Committee Rockville, 20 th September 2012 Sally.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.
Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.
Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
NAT Standards for Clinical Virology Sally Baylis, NIBSC SoGAT XX, Warsaw June 2007.
Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.
Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.
NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.
A multi-centre NAT evaluation study of run and trend control samples Harry van Drimmelen 1, Joe O’Donnellan 2, Rene Bax 1, Henrik Ullum 3 and the Danish.
Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.
Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
Maternofetal transmission of human parvovirus B19 genotype 3 in Ghana, West Africa D Candotti, K Danso, A Parsyan, A Dompreh, J- P Allain National Blood.
Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
Novel and Related Variant Parvoviruses in Human Plasma Jacqueline Fryer and Sally Baylis National Institute for Biological Standards and Control Eric Delwart.
SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.
Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
Work Package 2 „Implementation of the SRA” Call secretariat Annette Angermann & Wenke Apt Rome, 11 June 2015.
Saeko Mizusawa, Yoshiaki Okada
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
GRIFOLS PLASMA: genotype 2 vB19 sample
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Results of Recent EQA Panels for Blood Borne Viruses
Hepatitis C Virus RNA Real-Time Quantitative RT-PCR Method Based on a New Primer Design Strategy  Lida Chen, Wenli Li, Kuo Zhang, Rui Zhang, Tian Lu,
Roche Molecular Diagnostics
Update on CBER HIV-1 Subtype panel
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
1st International Standard for HIV-1 RNA NIBSC Code 97/656
Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5  Michael T.
SoGAT meeting XXI May (2009), Brussels, Belgium
Presentation transcript:

Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007

Replacement of the 2 nd International Standard for HCV RNA (96/798) Proposal made at SoGAT 2005 to replace the HCV RNA International Standard as requested by WHO Proposal made at SoGAT 2005 to replace the HCV RNA International Standard as requested by WHO Agreement that HCV 1a genotype would be sourced & would be anti-HCV negative and diluted in plasma rather than cryosupernatant Agreement that HCV 1a genotype would be sourced & would be anti-HCV negative and diluted in plasma rather than cryosupernatant

Candidate Standards for Evaluation 3 anti-HCV negative window period genotype 1a donations have been obtained 3 anti-HCV negative window period genotype 1a donations have been obtained The genotype of each has been confirmed by LiPA & DNA sequencing The genotype of each has been confirmed by LiPA & DNA sequencing Absence of other viral markers confirmed in these stocks Absence of other viral markers confirmed in these stocks Material has been freeze-dried in two batches Material has been freeze-dried in two batches Batch 1 (NIBSC Code 06/100), 2085 vials, fill CV = 0.62% Batch 1 (NIBSC Code 06/100), 2085 vials, fill CV = 0.62% Batch 2 (NIBSC code 06/102), 2100 vials, fill CV = 1.82% Batch 2 (NIBSC code 06/102), 2100 vials, fill CV = 1.82%

Panel for Collaborative study Sample 1 – 2 nd International Standard for HCV RNA (96/798) Sample 1 – 2 nd International Standard for HCV RNA (96/798) Sample 2 - new freeze-dried preparation 06/100 Sample 2 - new freeze-dried preparation 06/100 Sample 3 - new freeze-dried preparation 06/102 Sample 3 - new freeze-dried preparation 06/102 Sample 4 – liquid/frozen bulk material (NIBSC code 06/118) that was used to prepare Samples 2 & 3 Sample 4 – liquid/frozen bulk material (NIBSC code 06/118) that was used to prepare Samples 2 & 3

Collaborative Study Collaborative study commenced in November 2006 Collaborative study commenced in November 2006 Participants requested to test samples in four independent assays Participants requested to test samples in four independent assays 33 laboratories from 14 countries participated in the study 33 laboratories from 14 countries participated in the study 40 data sets received; 25 from quantitative assays & 15 from qualitative assays 40 data sets received; 25 from quantitative assays & 15 from qualitative assays NIBSC collated & analysed data NIBSC collated & analysed data

Types of Quantitative Assays Used by Participants Assay Code AssayNumber of Data-sets ABAbbott RealTime HCV7 BABayer Versant HCV RNA 3.0 (bDNA) 4 CTMCOBAS Ampliprep/COBAS TaqMan 6 CTMHHPS/COBAS TaqMan1 IHRTIn-house real-time3 MOCOBAS Amplicor HCV Monitor 4

Types of Qualitative Assays Used by Participants Assay Code AssayNumber of Data-sets AAmplicor HCV 2.02 ACCOBAS Amplicor HCV 2.01 ASCCOBAS Ampliscreen HCV 2.03 IHQIn-house qualitative1 IHRTQIn-house real-time qualitative3 PProcleix1* PUProcleix Ultrio1 PUTProcleix Ultrio (TIGRIS)1 TSCOBAS TaqScreen MPX1

Estimated IU/ml (log 10 ) from Quantitative Assays SampleNMean95% CISD%CV N - Number of laboratory estimates SD - Standard Deviation of log 10 estimates across laboratories

Estimated PCR Detectable Units/ml (log 10 ) from Qualitative Assays SampleNMean95% CISD%CV N - Number of laboratory estimates SD - Standard Deviation of log 10 estimates across laboratories

Overall Mean Potencies (log 10 IU/ml) Relative to Sample 1 SampleNMean95% CISD%CV N - Number of laboratory estimates SD - Standard Deviation of log 10 estimates across laboratories

Accelerated Degradation Studies Sample 2 Relative potencies of accelerated degradation samples with respect to Sample 2 stored at -20ºC (log 10 drop), qPCR analysis Stability appears similar to 96/790 and 96/798; studies on-going 96/798 from this study has not lost potency after >10 years storage at -20 ºC Incubation Time+4°C (10.5 months) +20°C (1 month) Sample

Proposal for 3 rd International Standard for HCV RNA Real-time & accelerated degradation data indicate that Sample 2 (06/100) is stable & suitable for long term use Real-time & accelerated degradation data indicate that Sample 2 (06/100) is stable & suitable for long term use Propose that 06/100 be established as the 3 rd International Standard for HCV RNA with a unitage of 5.19 log 10 IU/ml (4.89 log 10 IU/vial) Propose that 06/100 be established as the 3 rd International Standard for HCV RNA with a unitage of 5.19 log 10 IU/ml (4.89 log 10 IU/vial) Report will be submitted to ECBS by July Report will be submitted to ECBS by July

Acknowledgements Nita Shah & David Padley NIBSC Nita Shah & David Padley NIBSC Professor Ewa Brojer, Institute of Hematology & Blood Professor Ewa Brojer, Institute of Hematology & Blood Transfusion, Warsaw Transfusion, Warsaw Dr Richard Smith, National Genetics Institute, Dr Richard Smith, National Genetics Institute, Los Angeles Los Angeles Dr Vivienne James, HPA, Colindale Dr Vivienne James, HPA, Colindale Dr Michael Chudy, WHO, Geneva Dr Michael Chudy, WHO, Geneva Collaborative study participants Collaborative study participants

HCV RNA Collaborative Study Participants S Baylis, N ShahSouth Mimms, UK S Baylis, N ShahSouth Mimms, UK T Cuypers M KoppelmanAmsterdam, The Netherlands T Cuypers M KoppelmanAmsterdam, The Netherlands C DeferLille, France C DeferLille, France L FanningCork, Eire L FanningCork, Eire G GesuMilan, Italy G GesuMilan, Italy A GoglioBergamo, Italy A GoglioBergamo, Italy P GrantLondon, UK P GrantLondon, UK P IudiconeRome, Italy P IudiconeRome, Italy L Jarvis, A ClelandEdinburgh, UK L Jarvis, A ClelandEdinburgh, UK C JorkSpringe, Germany C JorkSpringe, Germany S KerbyBethesda, USA S KerbyBethesda, USA A Klotz, M GessnerVienna, Austria A Klotz, M GessnerVienna, Austria R MadejPleasanton, USA R MadejPleasanton, USA B MillerKarlsruhe, Germany B MillerKarlsruhe, Germany S MizusawaTokyo, Japan S MizusawaTokyo, Japan C NegruTimişoara, Romania C NegruTimişoara, Romania M NüblingLangen, Germany M NüblingLangen, Germany

HCV RNA Collaborative Study Participants JM PawlotskyCréteil, France JM PawlotskyCréteil, France M PecorariModena, Italy M PecorariModena, Italy G PisaniRome, Italy G PisaniRome, Italy A Portela MoreiraMadrid, Spain A Portela MoreiraMadrid, Spain S SauledaBarcelona, Spain S SauledaBarcelona, Spain H SchindlVienna, Austria H SchindlVienna, Austria G SchneiderDes Plaines, USA G SchneiderDes Plaines, USA A da SilvaLisbon, Portugal A da SilvaLisbon, Portugal R SmithLos Angeles, USA R SmithLos Angeles, USA S TassenBrentwood, UK S TassenBrentwood, UK P TaylorLondon, UK P TaylorLondon, UK A van der ZandenApeldoorn, The Netherlands A van der ZandenApeldoorn, The Netherlands YC YangTaipei, Taiwan YC YangTaipei, Taiwan S YerlyGeneva, Switzerland S YerlyGeneva, Switzerland M ZaccanelliTreviglio, Italy M ZaccanelliTreviglio, Italy

Update on the Stability of the HAV RNA International Standard Sally Baylis, Nita Shah & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007

Background – Hepatitis A Virus RNA IS The 1 st International Standard for HAV RNA (00/560) and a second batch (00/562) were prepared in Q1, 2001 The 1 st International Standard for HAV RNA (00/560) and a second batch (00/562) were prepared in Q1, /560 was evaluated in an international collaborative study, with data returned from 16 laboratories 00/560 was evaluated in an international collaborative study, with data returned from 16 laboratories The mean log 10 equivalents/ml were 5.29 (00/560) and 5.07 (00/562) The mean log 10 equivalents/ml were 5.29 (00/560) and 5.07 (00/562) 1 st International Standard (00/560) was established in 2003 with 50,000 IU/vial 1 st International Standard (00/560) was established in 2003 with 50,000 IU/vial ECBS noted that 00/562 may be a replacement for 00/560 ECBS noted that 00/562 may be a replacement for 00/560

Stability Data 00/560 & 00/562 Accelerated thermal degradation samples for 00/560 and 00/562, stored at +4ºC for ~6 years were tested in parallel with samples of 00/560 stored at -20 ºC Accelerated thermal degradation samples for 00/560 and 00/562, stored at +4ºC for ~6 years were tested in parallel with samples of 00/560 stored at -20 ºC 00/560 – a drop on 0.1 log 10 00/560 – a drop on 0.1 log 10 00/562 – a drop on 1.0 log 10 00/562 – a drop on 1.0 log 10 Conclude that 00/560 is highly stable Conclude that 00/560 is highly stable

Proposal to Replace the Parvovirus B19 DNA International Standard Sally Baylis, NIBSC SoGAT XX, Warsaw June 2007

Replacement of the Parvovirus B19 DNA IS 99/800 The 1 st International Standard for B19V DNA was established by the WHO ECBS in October 2000 The 1 st International Standard for B19V DNA was established by the WHO ECBS in October 2000 Estimated date of exhaustion of the IS will be 2008/9 at current rate of usage Estimated date of exhaustion of the IS will be 2008/9 at current rate of usage Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the collaborative study Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the collaborative study ECBS noted that BB (made from the same stock as AA) could be reserved for potential future use as a replacement standard ECBS noted that BB (made from the same stock as AA) could be reserved for potential future use as a replacement standard

Candidate 2 nd International Standard Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the original collaborative study Materials coded AA (99/800) & BB (99/802) showed no significant difference in potency in the original collaborative study ECBS noted that BB (prepared from the same stock as AA) could be reserved for potential future use as a replacement standard ECBS noted that BB (prepared from the same stock as AA) could be reserved for potential future use as a replacement standard Current study designed to demonstrate the equivalence of the candidate replacement (BB) to AA Current study designed to demonstrate the equivalence of the candidate replacement (BB) to AA Real-time data on samples AA & BB Real-time data on samples AA & BB Accelerated degradation data for samples AA & BB Accelerated degradation data for samples AA & BB